NORTH TEXAS (CBSDFW.COM) — A new study by the World Health Organization shows the COVID-19 treatment drug – known as remdesivir – does not prevent death among patients.

A CBS 11 iTeam investigation from earlier this week took an in-depth look at remdesivir.

READ MORE: Southern Border Patrol Agents Save Undocumented Migrant Who Fell Under Train, Remind Others 'Don't Trust Smugglers' 

The iTeam found studies have shown the drug can reduce the length of hospital stays in COVID-19 patients – usually shortening it from 15 days to 11.

But so far, studies have not shown that remdesivir has a significant effect on reducing death.

READ MORE: Dallas Baptist Falls 1 Game Short In Bid For 1st College World Series Berth

Results of the trial indicated that remdesivir and three other possible coronavirus treatment drugs — hydroxychloroquine, lopinavir/ritonavir and interferon — “appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients.”

Gilead Sciences – the maker of remdesivir – disputes the latest conclusion from WHO, saying that a large-scale trial they performed found the drug does, in fact, have life-saving benefits.

Remdesivir is currently the only antiviral drug authorized in the U.S. to treat COVID-19.

MORE NEWS: Child Tax Credit: How Much Will Your Monthly Check Be?

The CBS 11 iTeam report details more about remdesivir, including the controversy surrounding the price of the drug. Remdesivir costs more than $3,000 per treatment for patients with private insurance.